PT - JOURNAL ARTICLE AU - Zhai, Ting TI - Metformin Use and Thirty-Day Readmission Among Patients with Bipolar Disorders: A Propensity Score-matching Analysis AID - 10.1101/2024.07.28.24311148 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.28.24311148 4099 - http://medrxiv.org/content/early/2024/08/07/2024.07.28.24311148.short 4100 - http://medrxiv.org/content/early/2024/08/07/2024.07.28.24311148.full AB - Metformin may affect patients with multi-comorbid bipolar disorder through the integrated stress response. However, the relationship between them remains unclear. This study aimed to explore the relationship between metformin use and early (30-day) readmission in bipolar disorder patients. Data were extracted from the Medical Information Mart for Intensive Care IV database. Adult patients with a documented diagnosis of bipolar disorder were screened. Multivariable logistic regression and propensity score matching were used to investigate potential associations. Data on 1688 patients were included. The crude early (30-day) readmission was significantly higher in patients with metformin use (17/114 vs. 132/1574, p = 0.033). In the extended multivariable logistic models, the hazard ratio (HR) of metformin use was consistently significant in all models (HR range 1.87–2.99, p < 0.05 for all). After propensity score matching, the early (30-day) readmission remained significantly higher in the metformin use group (Mahalanobis matching, |t|>1.96). Although residual confounding cannot be excluded, metformin use is associated with higher readmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The datasets presented in the current study are available in the MIMIC-IV database (https://physionet.org/content/mimiciv/2.2/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets presented in the current study are available in the MIMIC-IV database (https://physionet.org/content/mimiciv/2.2/).